Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABBV
Strong BuyPremium GrowerFLAGAbbVie Inc. · Healthcare · United States · $451.5B · Avg Vol: $1.2B/d
AbbVie has quality Q72 and strong momentum M70 with a buyback on file, but value at V36 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
AbbVie Inc. is a global biopharmaceutical company focusing on the research, development, manufacturing, and sales of innovative therapies across immunology, oncology, neuroscience, and other specialty areas. It possesses a robust product pipeline and a portfolio of blockbuster drugs, such as Humira and Skyrizi, driving significant revenue and market share. AbbVie is a leading pharmaceutical innovator known for its strong R&D capabilities and strategic acquisitions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.1B | 54.3B | 56.3B | 61.2B | 1.8% | 64.4B | 67.6B | 73.5B | 9.6% |
| EPS | 6.69 | 2.75 | 2.42 | 2.39 | -29.0% | 3.54 | 3.35 | 3.89 | 27.6% |
| Shares | 1.8B | 1.8B | 1.8B | 1.8B | -0.1% | 1.8B | — | — | — |
| Debt | 63.3B | 59.4B | 67.1B | 67.5B | 2.2% | 70.9B | — | — | — |
| Equity | 17.3B | 10.4B | 3.3B | -3.3B | -56.1% | — | — | — | — |
| Op CF | 24.9B | 22.8B | 18.8B | 19.0B | -8.6% | 19.5B | — | — | — |
| Inv CF | -623.0M | -2.0B | -20.8B | -6.6B | — | — | — | — | — |
| Fin CF | -24.8B | -17.2B | -5.2B | -12.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABBV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABBV | AbbVie Inc.(you) | $451.5B | 86 | Strong Buy |
| RO.SW | Roche Holding AG | $360.3B | 85 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| NOVN.SW | Novartis AG | $290.6B | 81 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 89 | Strong Buy |
| PFE | Pfizer Inc. | $159.4B | 88 | Strong Buy |
| LLY | Eli Lilly and Company | $1.0T | 77 | Buy |
| MRK | Merck & Co., Inc. | $366.0B | 65 | Hold |
| AZN.ST | AstraZeneca PLC | $252.0B | 71 | Buy |
| JNJ | Johnson & Johnson | $645.9B | 66 | Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%